Literature DB >> 25744037

A female patient with incomplete hemophagocytic lymphohistiocytosis caused by a heterozygous XIAP mutation associated with non-random X-chromosome inactivation skewed towards the wild-type XIAP allele.

Xi Yang1, Akihiro Hoshino, Takashi Taga, Tomoaki Kunitsu, Yuhachi Ikeda, Takahiro Yasumi, Kenichi Yoshida, Taizo Wada, Kunio Miyake, Takeo Kubota, Yusuke Okuno, Hideki Muramatsu, Yuichi Adachi, Satoru Miyano, Seishi Ogawa, Seiji Kojima, Hirokazu Kanegane.   

Abstract

X-linked lymphoproliferative disease (XLP) is a rare inherited immunodeficiency that often leads to hemophagocytic lymphohistiocytosis (HLH). XLP can be classified as XLP1 or XLP2, caused by mutations in SH2D1A and XIAP, respectively. In women, X-chromosome inactivation (XCI) of most X-linked genes occurs on one of the X chromosomes in each cell. The choice of which X chromosome remains activated is generally random, although genetic differences and selective advantage may cause one of the X chromosomes to be preferentially inactivated. Here we describe three patients with pancytopenia, including one female patient, in a Japanese family with a novel XIAP mutation. All three patients exhibited deficient XIAP protein expression, impaired NOD2/XIAP signaling, and augmented activation-induced cell death. In the female patient, the paternally derived X chromosome was non-randomly and exclusively inactivated in her peripheral blood and hair root cells. In contrast to asymptomatic females, this patient exhibied non-random XCI skewed towards the wild-type XIAP allele. This is the first report of a female patient with incomplete HLH resulting from a heterozygous XIAP mutation in association with non-random XCI.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25744037     DOI: 10.1007/s10875-015-0144-6

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  22 in total

1.  XIAP mediates NOD signaling via interaction with RIP2.

Authors:  Andreas Krieg; Ricardo G Correa; Jason B Garrison; Gaëlle Le Negrate; Kate Welsh; Ziwei Huang; Wolfram T Knoefel; John C Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

2.  Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome.

Authors:  G Wengler; J B Gorlin; J M Williamson; F S Rosen; D H Bing
Journal:  Blood       Date:  1995-05-01       Impact factor: 22.113

3.  ACTN1 mutations cause congenital macrothrombocytopenia.

Authors:  Shinji Kunishima; Yusuke Okuno; Kenichi Yoshida; Yuichi Shiraishi; Masashi Sanada; Hideki Muramatsu; Kenichi Chiba; Hiroko Tanaka; Koji Miyazaki; Michio Sakai; Masatoshi Ohtake; Ryoji Kobayashi; Akihiro Iguchi; Gen Niimi; Makoto Otsu; Yoshiyuki Takahashi; Satoru Miyano; Hidehiko Saito; Seiji Kojima; Seishi Ogawa
Journal:  Am J Hum Genet       Date:  2013-02-21       Impact factor: 11.025

Review 4.  Familial and acquired hemophagocytic lymphohistiocytosis.

Authors:  G E Janka
Journal:  Annu Rev Med       Date:  2012       Impact factor: 13.739

5.  Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency).

Authors:  Jana Pachlopnik Schmid; Danielle Canioni; Despina Moshous; Fabien Touzot; Nizar Mahlaoui; Fabian Hauck; Hirokazu Kanegane; Eduardo Lopez-Granados; Ester Mejstrikova; Isabelle Pellier; Lionel Galicier; Claire Galambrun; Vincent Barlogis; Pierre Bordigoni; Alain Fourmaintraux; Mohamed Hamidou; Alain Dabadie; Françoise Le Deist; Filomeen Haerynck; Marie Ouachée-Chardin; Pierre Rohrlich; Jean-Louis Stephan; Christelle Lenoir; Stéphanie Rigaud; Nathalie Lambert; Michèle Milili; Claudin Schiff; Helen Chapel; Capucine Picard; Geneviève de Saint Basile; Stéphane Blanche; Alain Fischer; Sylvain Latour
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

6.  A new assay for the analysis of X-chromosome inactivation based on methylation-specific PCR.

Authors:  T Kubota; S Nonoyama; H Tonoki; M Masuno; K Imaizumi; M Kojima; K Wakui; M Shimadzu; Y Fukushima
Journal:  Hum Genet       Date:  1999-01       Impact factor: 4.132

7.  Clinical and genetic characteristics of XIAP deficiency in Japan.

Authors:  Xi Yang; Hirokazu Kanegane; Naonori Nishida; Toshihiko Imamura; Kazuko Hamamoto; Ritsuko Miyashita; Kohsuke Imai; Shigeaki Nonoyama; Kazunori Sanayama; Akiko Yamaide; Fumiyo Kato; Kozo Nagai; Eiichi Ishii; Menno C van Zelm; Sylvain Latour; Xiao-Dong Zhao; Toshio Miyawaki
Journal:  J Clin Immunol       Date:  2012-01-08       Impact factor: 8.317

8.  A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency.

Authors:  Rebecca A Marsh; Joyce Villanueva; Kejian Zhang; Andrew L Snow; Helen C Su; Lisa Madden; Rajen Mody; Brenda Kitchen; Dan Marmer; Michael B Jordan; Kimberly A Risma; Alexandra H Filipovich; Jack J Bleesing
Journal:  Cytometry B Clin Cytom       Date:  2009-09       Impact factor: 3.058

9.  Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency.

Authors:  Taizo Wada; Hirokazu Kanegane; Kazuhide Ohta; Fumiyo Katoh; Toshihiko Imamura; Yozo Nakazawa; Ritsuko Miyashita; Junichi Hara; Kazuko Hamamoto; Xi Yang; Alexandra H Filipovich; Rebecca A Marsh; Akihiro Yachie
Journal:  Cytokine       Date:  2013-09-29       Impact factor: 3.861

10.  Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation.

Authors:  Mindy Anderson-Cohen; Steve M Holland; Doug B Kuhns; Thomas A Fleisher; Li Ding; Sebastian Brenner; Harry L Malech; Joachim Roesler
Journal:  Clin Immunol       Date:  2003-12       Impact factor: 3.969

View more
  8 in total

Review 1.  Pediatric hemophagocytic lymphohistiocytosis.

Authors:  Scott W Canna; Rebecca A Marsh
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

2.  Identification of Germline Non-coding Deletions in XIAP Gene Causing XIAP Deficiency Reveals a Key Promoter Sequence.

Authors:  Zineb Sbihi; Kay Tanita; Camille Bachelet; Christine Bole; Fabienne Jabot-Hanin; Frederic Tores; Marc Le Loch; Radi Khodr; Akihiro Hoshino; Christelle Lenoir; Matias Oleastro; Mariana Villa; Lucia Spossito; Emma Prieto; Silvia Danielian; Erika Brunet; Capucine Picard; Takashi Taga; Shimaa Said Mohamed Ali Abdrabou; Takeshi Isoda; Masafumi Yamada; Alejandro Palma; Hirokazu Kanegane; Sylvain Latour
Journal:  J Clin Immunol       Date:  2022-01-09       Impact factor: 8.317

Review 3.  How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease.

Authors:  Ole Haagen Nielsen; Eric Charles LaCasse
Journal:  Genet Med       Date:  2016-07-14       Impact factor: 8.822

Review 4.  Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis.

Authors:  Rebecca A Marsh
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

Review 5.  Current Flow Cytometric Assays for the Screening and Diagnosis of Primary HLH.

Authors:  Samuel Cern Cher Chiang; Jack J Bleesing; Rebecca A Marsh
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

6.  Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan.

Authors:  Shintaro Ono; Tsubasa Okano; Akihiro Hoshino; Masakatsu Yanagimachi; Kazuko Hamamoto; Yozo Nakazawa; Toshihiko Imamura; Masaei Onuma; Hidetaka Niizuma; Yoji Sasahara; Hiroshi Tsujimoto; Taizo Wada; Reiko Kunisaki; Masatoshi Takagi; Kohsuke Imai; Tomohiro Morio; Hirokazu Kanegane
Journal:  J Clin Immunol       Date:  2016-11-04       Impact factor: 8.317

7.  Eosinophilic colitis in a boy with a novel XIAP mutation: a case report.

Authors:  Jiamei Tang; Xiaoying Zhou; Lan Wang; Guorui Hu; Bixia Zheng; Chunli Wang; Yan Lu; Yu Jin; Hongmei Guo; Zhifeng Liu
Journal:  BMC Pediatr       Date:  2020-04-18       Impact factor: 2.125

Review 8.  Evolution of Our Understanding of XIAP Deficiency.

Authors:  Anne C A Mudde; Claire Booth; Rebecca A Marsh
Journal:  Front Pediatr       Date:  2021-06-17       Impact factor: 3.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.